EU/3/06/357

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in March 2009 on request of the sponsor.

On 16 February 2006, orphan designation (EU/3/06/357) was granted by the European Commission to Prosensa B.V., The Netherlands, for 2'-O-methyl-phosphorothioate oligonucleotide for the treatment of Duchenne muscular dystrophy.

Key facts

Active substance
2'-O-methyl-phosphorothioate oligonucleotide
Disease / condition
Treatment of Duchenne muscular dystrophy
Date of decision
15/02/2006
Outcome
Withdrawn
Orphan decision number
EU/3/06/357

Sponsor's contact details

Prosensa B.V.
Einsteinweg 55
2333 CC Leiden
The Netherlands
Telephone: +31 71 527 42 02
E-mail: contact@prosensa.nl

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Duchenne Parent Project UK (PPUK)
    Epicentre
    41 West Street
    London
    E11 4LJ
    United Kingdom
    Telephone: +44 20 85 56 99 55
    E-mail: info@ppuk.org
  • AFM : Association Française contre les Myopathies
    BP 59
    1 Rue de l'Internationale
    91002 Evry Cedex
    France
    Telephone: +33 1 69 47 28 28 / +33 81 08 11 088
    Telefax: +33 1 60 77 12 16
    E-mail: afm@afm.genethon.fr
  • DGM : Deutsche Gesellschaft für Muskelkranke e.V.
    Im Moos 4
    79112 Freiburg
    Germany
    Telephone: +49 76 65 94 470
    Telefax: +49 76 65 94 47 20
    E-mail: info@dgm.or

How useful was this page?

Add your rating